8-KOther Events

Merck & Co., Inc. 8-K Report (Oct 21, 2002)

Filed October 21, 2002For Securities:MRK

Summary

This 8-K filing by Schering-Plough Corporation, on behalf of the Merck/Schering-Plough Pharmaceuticals joint venture, announces a significant regulatory milestone: the marketing approval of EZETROL(TM) (ezetimibe) 10 mg tablets in Germany. This approval allows for its use as a monotherapy and in combination with all marketed statins for the treatment of elevated cholesterol levels. This marks the initial step in the joint venture's strategy to gain marketing authorization across the European Union. Investors should note that the U.S. Food and Drug Administration (FDA) is currently reviewing the New Drug Application (NDA) for ezetimibe, which will be marketed as ZETIA(TM) in the United States. The approval in Germany and the ongoing FDA review represent key developments for the Merck/Schering-Plough Pharmaceuticals joint venture, potentially broadening the treatment options for hypercholesterolemia patients and driving future revenue growth for both parent companies.

Key Highlights

  • 1Merck/Schering-Plough Pharmaceuticals joint venture received marketing approval for EZETROL(TM) (ezetimibe) in Germany on October 17, 2002.
  • 2EZETROL(TM) is approved for use alone and in combination with all marketed statins for elevated cholesterol.
  • 3This German approval is the first step towards seeking marketing authorization throughout the European Union.
  • 4The U.S. New Drug Application (NDA) for ezetimibe (to be marketed as ZETIA(TM) in the US) was submitted to the FDA on December 27, 2001, and is currently under review.
  • 5This development signifies a potential new product launch for the joint venture in major markets.
  • 6The filing also references underlying agreements governing the joint venture: the Cholesterol Governance Agreement and the Master Agreement.

Frequently Asked Questions

The approval of EZETROL(TM) (ezetimibe) in Germany is a key regulatory milestone for the Merck/Schering-Plough Pharmaceuticals joint venture. It signifies the first marketing authorization for this new cholesterol-lowering drug in Europe, paving the way for potential EU-wide approval and representing a significant step towards commercialization.

The New Drug Application (NDA) for ezetimibe, which will be marketed as ZETIA(TM) in the U.S., was submitted to the FDA on December 27, 2001. The filing indicates that the application is currently under review, but it does not provide a specific timeline for potential FDA approval or U.S. market launch.

The Merck/Schering-Plough Pharmaceuticals joint venture is a collaboration between Merck & Co., Inc. and Schering-Plough Corporation. Its purpose is to develop and market new prescription medicines for cholesterol management worldwide, with the exception of Japan.

This 8-K filing primarily announces a regulatory event and does not contain specific financial statements or immediate financial guidance. However, the approval and potential future launch of ezetimibe are expected to impact the revenue streams of the Merck/Schering-Plough Pharmaceuticals joint venture and, consequently, the financial performance of Merck & Co. and Schering-Plough.